Navigation Links
Data From Phase 2 Clinical Studies of Telotristat Etiprate in Patients With Carcinoid Syndrome to be Presented at North American Neuroendocrine Tumor Society Meeting
Date:10/21/2011

yndrome, carcinoid syndrome and rheumatoid arthritis, all of which were discovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.  For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking statements," including statements relating to Lexicon's clinical development of telotristat etiprate (LX1032), including characterizations of the results of and projected timing of clinical trials of such compounds, and the potential therapeutic and commercial potential of telotristat etiprate (LX1032). This press release also contains forward-looking statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct clinical development of telotristat etiprate (LX1032) and preclinical and clinical development of its other potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lex
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... May 21, 2013 Reaching a critical milestone ... National Association of Boards of Pharmacy ® (NABP ... domain suffix has passed the Internet Corporation for Assigned ... launch the .PHARMACY gTLD by the end of 2013, ... online pharmacies and related entities that are located in ...
(Date:5/21/2013)... -- Concord Medical Services Holdings Limited ("Concord Medical" or ... specialty hospital management solution provider and operator of the ... China and the parent of Chang,an Hospital, today reported ... ended March 31, 2013 [1] . First ... consists of net revenues generated from the network business ...
(Date:5/21/2013)... LAWRENCE, Mass. , May 21, 2013  NxStage ... manufacturer of innovative dialysis products, today announced that it ... home, critical care and in-center products to DaVita, the ... (Logo: http://photos.prnewswire.com/prnh/20110503/MM94799LOGO ) For the ... the United States , NxStage has executed a ...
Breaking Medicine Technology:NABP's .PHARMACY Proposal Passes Initial ICANN Evaluation 2NABP's .PHARMACY Proposal Passes Initial ICANN Evaluation 3Concord Medical Reports First Quarter 2013 Financial Results 2Concord Medical Reports First Quarter 2013 Financial Results 3Concord Medical Reports First Quarter 2013 Financial Results 4Concord Medical Reports First Quarter 2013 Financial Results 5Concord Medical Reports First Quarter 2013 Financial Results 6Concord Medical Reports First Quarter 2013 Financial Results 7Concord Medical Reports First Quarter 2013 Financial Results 8Concord Medical Reports First Quarter 2013 Financial Results 9Concord Medical Reports First Quarter 2013 Financial Results 10Concord Medical Reports First Quarter 2013 Financial Results 11Concord Medical Reports First Quarter 2013 Financial Results 12Concord Medical Reports First Quarter 2013 Financial Results 13NxStage Announces New Agreements with DaVita 2
... Isis Pharmaceuticals,Inc. (Nasdaq: ISIS ) announced ... from a randomized Phase 2 clinical trial of,OGX-011 ... arm"),compared to docetaxel and prednisone alone ("the control ... cancer. The current 10.6,month median overall survival ...
... DIEGO, Dec. 3 Vical Incorporated,(Nasdaq: VICL ... with EIP,Eczacibasi Ilac Pazarlama A.S. (EIP) for sales and ... and the Turkish,Republic of Northern Cyprus. EIP has agreed ... to pay Vical upfront and milestone payments,plus a specified ...
Cached Medicine Technology:Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study 2Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study 3Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study 4Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 2Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 3Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 4Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 5
(Date:5/21/2013)... Focus, a non-profit organization striving to improve the living ... Corridor region, is releasing results for its 2013 Creative ... May 23rd at 10:30 a.m. The survey follows ... The survey is a critical component to the organizations’ ... and retain people of diverse backgrounds, cultures and beliefs ...
(Date:5/21/2013)... Colo. (May 21, 2013) A paper recently published ... and co-written by physicians and scientists at the University ... genetic risk factor for pulmonary fibrosis can be used ... disease. , Researchers looked at a fairly common variant ... a component of the mucous produced by the bronchial ...
(Date:5/21/2013)... for scientific and technological research So Paulo Research Foundation, ... an investment estimated in US$ 680 million to support ... period of up to eleven years, subject to continuation ... Funding for the 17 RIDCs will come from FAPESP ... personnel, and infrastructure). Host institutions will participate in a ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Today, Zane ... HSA and FSA accounts. Zane Benefits, which provides ... benefits, is the leader in defined contribution ... arrangements . , According to Zane Benefits’ website, the ... was signed into law in 2010 and impacts many ...
(Date:5/21/2013)... 21, 2013 While North Carolina is ... comprehensive travel guides. Brunswick Plantation & Golf Resort is ... include access to 27 holes of "Top10" championship golf. ... North Carolina, knowing the Top 10 from ... away the overwhelming task of selecting the course to ...
Breaking Medicine News(10 mins):Health News:Diversity Focus Announces Results from 2013 Creative Corridor Survey at News Conference on Thursday, May 23rd at 10:30 a.m. 2Health News:Researchers find genetic risk factor for pulmonary fibrosis 2Health News:Research at the cutting edge of knowledge 2Health News:Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts 2Health News:Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts 3Health News:Brunswick Plantation & Golf Resort Named in Top 10 Golf Resorts in North Carolina 2
... Medicine at Harvard Medical School and Beth Israel Deaconess ... Lectureship at the annual meeting of the Federation of ... month in Washington, DC. Named in honor of ... for radioimmunoassay led to discoveries that have helped to ...
... By Maureen Salamon HealthDay Reporter , THURSDAY, ... N.C., was in her early forties when she developed anorexia ... "In the middle of a disorder like that, you ... you," she said. Luckily, Hodgin sought the care of ...
... people develop diabetes because they don,t have enough pancreatic beta ... sugar levels. But what if other cells ... cells? Could we potentially cure diabetes? Researchers ... an important step in that direction. They report in the ...
... PHILADELPHIA Black cardiac arrest victims are more likely ... a large black population than when they,re brought to hospitals ... research from the University of Pennsylvania School of Medicine. The ... American Heart Journal . The Penn team found that, ...
... Tierney, M.D., president and CEO of the Regenstrief Institute ... Indiana University School of Medicine, received a 2011 Distinguished ... and Education Meeting on April 28 in Washington, DC. ... Achievement and Contribution to Clinical and Translational Science. He ...
... Vision and Ophthalmology (ARVO) is pleased to announce its 2011 ... the ARVO 2011 Annual Meeting, May 1 5, in ... MD, PhD, FARVO, Mildred Weisenfeld Award for Excellence in Ophthalmology: ... James T. Rosenbaum, MD, FARVO, Cogan Award: Andrew J. Fischer, ...
Cached Medicine News:Health News:Christos Mantzoros honored by Federation of the American Societies for Experimental Biology 2Health News:Bringing Partner Into Anorexia Treatment May Aid Recovery 2Health News:Bringing Partner Into Anorexia Treatment May Aid Recovery 3Health News:Researchers discover mechanism that could convert certain cells into insulin-making cells 2Health News:Black cardiac arrest patients more likely to be admitted to hospitals with lowest survival rates 2Health News:Tierney named 2011 Clinical and Translational Research Distinguished Investigator 2Health News:2011 ARVO Award recipients honored at annual meeting 2Health News:2011 ARVO Award recipients honored at annual meeting 3
... The BiPAP Pro with Bi-Flex bi-level ... time that the BiPAP Pro takes to ... includes Digital Auto-Trak Sensitivity™ which automatically triggers ... expiratory pressures based on the patients breathing ...
... Gradient Lipoprotein Electrophoresis System (PGGE) is ... as low density lipoproteins (LDL) and ... particle size using nondenaturing pore gradient ... PAGE and short DNA sequencing runs. ...
... The Lipoprint System is a high resolution ... routinely tested by other methods. The test procedure ... than three hours. Any abnormal value is clearly ... the highly atherogenic, small dense LDL in red ...
... This control monitors spinal fluid analyte methods ... Fluid Control is packaged in dropper-tip bottles ... the need for pipets and minimizing waste. ... most major chemistry analyzers and nephelometers: Abbott ...
Medicine Products: